手术联合放化疗治疗晚期下咽癌的生存及安全性评价  

Survival and safety evaluation of surgery combined with chemoradiotherapy for advanced hypopharyngeal carcinoma

作　　者：程翠 孙利 蔡丰[1] 江浩[1] 孙谦[1] Cheng Cui;Sun Li;Cai Feng;Jiang Hao;Sun Qian(Department of Radiation Oncology,First Affiliated Hospital of Bengbu Medical University,Bengbu 233004,China)

机构地区：[1]蚌埠医学院第一附属医院肿瘤放疗科,233004

出　　处：《国际肿瘤学杂志》2021年第2期80-85,共6页Journal of International Oncology

基　　金：安徽省临床医学优先发展重点专科项目(卫教科2018-291)。

摘　　要：目的比较晚期下咽鳞状细胞癌患者接受手术联合放化疗与放化疗治疗的生存情况及不良反应,并分析患者预后影响因素。方法回顾性分析2013年8月至2018年12月就诊于蚌埠医学院第一附属医院肿瘤放疗科的78例晚期下咽鳞状细胞癌患者的临床病理资料,根据治疗方式将患者分为手术联合放化疗组(n=27)和放化疗组(n=51)。中位随访时间为46(20~84)个月,主要观察指标为总生存期(OS)、无进展生存期(PFS)和局部控制率(LCR),采用Cox回归模型分析患者预后影响因素。结果截至2020年7月31日,78例晚期下咽鳞状细胞癌患者死亡51例,其中局部复发6例、远处转移11例、其他原因34例(包括大出血15例、恶病质15例、其他疾病4例);手术联合放化疗组死亡12例,占手术联合放化疗组的44.44%;放化疗组死亡39例,占放化疗组的76.47%。78例患者的1、3、5年OS率分别为57.7%、36.3%、27.2%,1、2、3年PFS率分别为49.5%、38.7%和32.6%,1、2、3年LCR分别为53.4%、40.0%、34.2%。其中手术联合放化疗组患者1、3、5年OS率分别为74.1%、50.1%、44.6%,放化疗组分别为49.0%、29.3%、12.8%,差异有统计学意义(χ^(2)=5.142,P=0.023);手术联合放化疗组患者1、2、3年PFS率分别为62.1%、54.3%、44.4%,放化疗组分别为43.1%、30.6%、26.7%,差异无统计学意义(χ^(2)=3.222,P=0.073);手术联合放化疗组患者1、2、3年LCR分别为69.8%、54.3%、44.4%,放化疗组分别为45.1%、32.9%、29.6%,差异无统计学意义(χ^(2)=3.576,P=0.059)。单因素分析结果显示,肿瘤T分期(χ^(2)=7.140,P=0.008)、N分期(χ^(2)=4.493,P=0.034)、治疗方式(χ^(2)=5.142,P=0.023)均为晚期下咽鳞状细胞癌患者OS的独立影响因素;T分期(χ^(2)=5.807,P=0.016)和N分期(χ^(2)=6.587,P=0.010)均为晚期下咽鳞状细胞癌患者PFS的独立影响因素。多因素分析结果显示,肿瘤T分期(HR=2.121,95%CI为1.142~3.938,P=0.017)、N分期(HR=2.088,95%CI为1.144~3.811,P=0.016)、治疗方式(Objective To compare the survival rate and adverse reactions of patients with advanced hypopharyngeal squamous cell carcinoma undergoing surgery combined with chemoradiotherapy,and to analyze the prognostic factors of patients.Methods The clinicopathologic data of 78 patients with advanced hypopharyngeal squamous cell carcinoma admitted to the Department of Radiation Oncology of the First Affiliated Hospital of Bengbu Medical University from August 2013 to December 2018 were retrospectively analyzed.The patients were divided into surgery combined with chemoradiotherapy group(n=27)and chemoradiotherapy group(n=51)according to different treatment methods.The median follow-up time was 46 months(20-84 months).The main observation indicators were overall survival(OS),progression-free survival(PFS)and local control rate(LCR).Cox regression model was used to analyze the prognostic factors.Results Until July 31,2020,51 of the 78 patients with advanced hypopharyngeal squamous cell carcinoma died,including 6 cases of local recurrence,11 cases of distant metastasis,and 34 cases of other causes(15 cases of hemorrhage,15 cases of cachexia,and 4 cases of other diseases).In the surgery combined with chemoradiotherapy group,12 patients died,accounting for 44.44%.In the chemoradiotherapy group,39 patients died,accounting for 76.47%.The 1-,3-and 5-year OS rates of 78 patients were 57.7%,36.3%and 27.2%respectively,the 1-,2-and 3-year PFS rates were 49.5%,38.7%and 32.6%respectively,and the 1-,2-and 3-year LCR were 53.4%,40.0%and 34.2%respectively.The 1-,3-and 5-year OS rates in the surgery combined with chemoradiotherapy group were 74.1%,50.1%and 44.6%,and those in the chemoradiotherapy group were 49.0%,29.3%and 12.8%,with a statistically significant difference(χ^(2)=5.142,P=0.023).The 1-,2-and 3-year PFS rates in the surgery combined with chemoradiotherapy group were 62.1%,54.3%and 44.4%,and those in the chemoradiotherapy group were 43.1%,30.6%and 26.7%,with no statistically significant difference(χ^(2)=3.222,P=0.073).The 1-,2-an

关 键 词：下咽肿瘤 外科手术 化放疗 综合疗法 预后 

分 类 号：R739.63[医药卫生—肿瘤]